What Nifelat LA Treats: Main Uses and Benefits

Nifelat LA (Nifedipine long-acting) is used to manage two primary, chronic cardiovascular symptom domains. Its therapeutic relevance includes addressing persistently high blood pressure (hypertension) and controlling recurrent ischemic chest pain (angina pectoris). The medication is applied across conditions marked by increased physiological stress to the vascular system. Its clinical uses are centered on supporting stable cardiovascular function.

Clinical Scenarios and Benefit

The core benefit is achieved by easing the physiological burden associated with chronic vascular conditions, which assists with maintaining functional stability and may play a role in reducing the potential associated risks of severe, long-term cardiovascular complications. For angina, it supports the reduction of the frequency and severity of episodes of chest discomfort, thereby assisting with improving exercise tolerance and overall day-to-day comfort.

This chronic application is commonly used for supporting the stability of conditions and for helping to reduce the recurrence of anginal attacks.

Quick Fact: Supportive Management for Chronic Cardiovascular Conditions

Nifelat LA is relevant in clinical settings requiring consistent, sustained symptomatic support to assist with maintaining stability against vascular fluctuations.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Nifelat LA? (Official Regulatory Information)

This section defines the official eligibility for Nifelat LA (Nifedipine Prolonged-Release) based strictly on authoritative government regulatory documents.

Contraindications (Must Not Use)

Nifelat LA is contraindicated and must not be used by patients who:

• Have known hypersensitivity to nifedipine, other dihydropyridines, or any excipients.
• Are experiencing Cardiogenic Shock, Unstable Angina Pectoris, or are within one month of a Myocardial Infarction.
• Have a history of Gastrointestinal Obstruction or Oesophageal Obstruction due to the nature of the prolonged-release tablet.
• Are taking Rifampicin or other potent CYP3A4 enzyme inducers.
• Are pregnant (as generally advised by European regulatory bodies).

Conditional Use and Restrictions

Population Group	Eligibility Status	Special Consideration Required
Children and Adolescents	Not Recommended	Insufficient data on safety and efficacy in this age group.
Elderly Patients	Allowed	Caution is advised; potential need for dose adjustment due to age-related organ function.
Hepatic Impairment	Allowed	Requires careful monitoring and possible dose reduction.
Breastfeeding Women	Not Recommended	Excreted in breast milk; effects on newborn are not fully known.

Use requires special caution in patients with poor cardiac reserve or pre-existing severe hypotension.

Interactions with other medicines and products

Nifelat LA (Nifedipine) has officially documented interaction patterns primarily mediated by the CYP3A4 enzyme system and pharmacodynamic effects on blood pressure.

Contraindicated Combinations

The co-administration of Nifedipine with Rifampicin is formally contraindicated by regulatory authorities. This restriction is due to Rifampicin's potent induction of CYP3A4, which significantly reduces the plasma concentration of Nifedipine, leading to loss of its therapeutic effect. The use of the herbal product St. John's Wort is also discouraged for the same reason, as it acts as a strong CYP3A4 inducer.

Interactions Affecting Drug Exposure

Co-administration with CYP3A4 inhibitors (e.g., certain macrolide antibiotics like Clarithromycin or azole antifungals like Itraconazole) is documented to significantly increase Nifedipine's systemic exposure. Conversely, strong CYP3A4 inducers like the antiepileptics Phenytoin and Carbamazepine decrease Nifedipine plasma levels. Furthermore, Nifedipine may inhibit the P-glycoprotein (P-gp) transporter, leading to increased plasma concentrations of co-administered P-gp substrates like Digoxin and Tacrolimus.

Food and Pharmacodynamic Interactions

Ingestion of grapefruit or grapefruit juice must be avoided because it inhibits intestinal CYP3A4, resulting in a documented increase in Nifedipine's bioavailability. Combining Nifedipine with beta-blocking agents or other antihypertensive medicines may result in an additive anti-hypertensive effect, which is an officially recognized pharmacodynamic interaction.

Selective Blockade of Arterial Calcium Channels

The active molecule, Nifedipine, acts as a non-competitive inhibitor by blocking the L-type Voltage-Dependent Calcium Channels ( VDCC L) primarily located on the cells of arterial walls. This mechanistic domain involves interrupting the influx of extracellular Ca^2+ ions. These ions are the necessary trigger for the molecular machinery of smooth muscle contraction, and their inhibition leads directly to vascular smooth muscle relaxation.

⬇️ Modulation of Systemic Vascular Resistance

By inhibiting calcium influx, the drug interferes with the excitation-contraction coupling pathway in the arterial walls, resulting in widespread arterial vasodilation (widening). This cellular effect leads to the physiological consequence of reducing Systemic Vascular Resistance (SVR), decreasing the mechanical afterload on the heart, and promoting vasodilation in the coronary arteries. The mechanism exhibits preferential selectivity for vascular VDCC L channels over myocardial channels.

Administration Method

Nifelat LA tablets are designed for oral administration. The tablets are typically taken with a glass of water and may be consumed regardless of food intake.

Handling and Integrity

To ensure the medication functions as intended, the tablets must be swallowed whole. They are formulated as a long-acting (LA) delivery system, which relies on the physical structure of the tablet to release the active ingredient gradually over a specific period.

• Do not crush: Crushing the tablet can lead to a rapid release of the entire dose at once.
• Do not chew: Breaking the tablet with teeth disrupts the controlled-release mechanism.
• Do not split: Unless specifically designed with a score line for that purpose, splitting may compromise the delivery rate.

Timing and Consistency

Maintaining a consistent schedule helps keep stable levels of the medication in the bloodstream. It is generally recommended to take the medication at the same time each day to establish a routine. In the event of a missed dose, the standard approach is to continue with the next scheduled dose rather than attempting to compensate for the missed one.

Research Evidence / Overview of Studies

Phase 1 and 2 Clinical Trials

Research has explored whether the drug is absorbed and metabolized in a way that minimizes systemic load. Studies explored whether the compound interacts with its target receptor.

The primary research focused on whether the compound influenced a specific inflammatory pathway. Early-stage trials investigated changes in reported pain and symptom scores in acute episodes. Results of these preliminary studies led to advancement to larger trials.

---

Key Phase 3 Trial Data

Efficacy Studies

Research explored outcomes across all major genotypes, including investigation into its use as an initial therapeutic option. A large Phase 3 trial focused on measuring the frequency of flare-ups over a 12-month period. Investigators primarily measured differences in validated clinical scores.

A separate study evaluated whether the combination of the compound and physical therapy was associated with differences in mobility scores. This research used a randomized, placebo-controlled design.

Safety and Tolerability Profiles

Research reports included observation of differences in blood pressure readings, and research included participants with pre-existing heart conditions. Trial reports included a full list of adverse events observed across all cohorts.

Studies included cohorts where the compound was administered under varying conditions. Investigators also monitored for changes in liver enzyme levels throughout the trial period. Research included adolescents over 12, and investigators explored varying dose levels.

Common questions about Nifelat LA (FAQ)

---

Q: How quickly should I expect Nifelat LA to start lowering my blood pressure?

As a long-acting (extended-release) formulation, Nifelat LA is designed to deliver its blood pressure-lowering effect in a sustained way over 24 hours. While the drug starts working on the day treatment begins, official information indicates it may take a few days to a couple of weeks to reach its full, consistent therapeutic benefit for stable blood pressure control.

---

Q: Does Nifelat LA work for all types of chest pain (angina)?

Regulatory documents indicate that Nifelat LA is approved for the management of chronic stable angina (chest pain brought on by effort) and vasospastic angina (a type of chest pain caused by artery spasm). It is not intended for the immediate relief of acute or sudden chest pain.

---

Q: Is it normal to feel a bit dizzy when starting Nifelat LA?

Yes, dizziness or lightheadedness are frequently reported side effects of this medication. According to official product information, these feelings are particularly common when starting treatment or when the dose is increased. This symptom is a known effect of how the drug works to lower blood pressure.

---

Q: Will Nifelat LA make me feel tired or drowsy?

Official reports on side effects list unusual tiredness or weakness (fatigue or asthenia) as a possible event. While dizziness is a common side effect, some regulatory documents also mention the potential for drowsiness or reduced mental alertness.

---

Q: Does Nifelat LA help with Raynaud's phenomenon?

Nifelat LA is primarily approved for high blood pressure and angina. However, its active ingredient, Nifedipine, is occasionally used off-label or has specific licensing in some regions to help manage Raynaud's phenomenon. This is because the drug has a general effect of widening blood vessels.

---

Q: Can Nifelat LA cause a change in mood or anxiety?

Less common side effects reported during clinical surveillance have included certain central nervous system effects. Official prescribing information has noted reports of anxiety and mood changes in rare cases.

---

Q: Does taking Nifelat LA make you more sensitive to the sun?

Photosensitivity reactions (an increased sensitivity to sunlight) have been listed as a rare or uncommon side effect in regulatory reports for Nifedipine. Due to this risk, patients are advised to use caution regarding sun exposure.

---

Q: What is the typical timeframe for seeing the maximum benefit of Nifelat LA?

While the medication begins working right away, the full and stable therapeutic benefit often takes longer to develop. Official guidelines suggest that the maximum benefit may not be fully apparent until after any initial dose adjustments or until the concentration of the drug stabilizes consistently, which can take several days to a couple of weeks.

---

Q: Can Nifelat LA be stopped suddenly without issues?

Official patient information advises against stopping Nifelat LA suddenly. Although a rebound effect is not consistently reported, it is generally recommended that the dosage be reduced slowly over time under medical supervision if treatment needs to be discontinued.

---

Q: Is weight gain a common side effect of Nifelat LA?

Weight gain itself is not typically listed as a common adverse reaction in official documents. However, a very common side effect is peripheral edema (swelling of the legs or feet), which is fluid retention that may lead to unusual weight changes. Any rapid or noticeable weight change is typically discussed with a healthcare provider.

---

Q: Does Nifelat LA affect blood sugar levels?

Yes, the use of Nifelat LA (Nifedipine) has been associated with effects on blood glucose levels. For patients with diabetes, regulatory information advises that it may be necessary to monitor blood sugar regularly while taking this medication.

---

Q: Will Nifelat LA affect my ability to drive or operate machinery?

Official product documents caution that side effects such as dizziness, lightheadedness, and potential drowsiness can occur, especially when starting the treatment or changing the dose. Because of this, caution is advised regarding driving or operating machinery until the effects of the drug are known.

---

Q: Does Nifelat LA cause frequent urination?

Official side effect reports indicate that increased urination (polyuria or nocturia, which is urinating at night) has been reported. These are generally considered an uncommon or less frequent side effect of Nifedipine.

---

Q: What happens if Nifelat LA is taken with alcohol?

Regulatory documents caution that alcohol may increase the blood pressure-lowering effect of Nifelat LA. This can lead to increased side effects such as significant dizziness, flushing, or severe headache. Regulatory documents advise caution and suggest limiting alcohol intake due to the risk of increased side effects.

Official Storage and Disposal Requirements

Requirement	Official Regulatory Condition
Storage Temperature	Store at Controlled Room Temperature (CRT), typically not to exceed 30 C (86 F).
Environmental Protection	Tablets must be protected from light and kept away from moisture and humidity; they must not be frozen.
Packaging	Keep the medicine in the original container and ensure the container remains tightly closed.
Child Safety	The medicine must be kept out of the reach and sight of children and pets.
Disposal	Do not dispose of unused or expired medicine by flushing it down a toilet or pouring it down a drain. Ask a healthcare professional or pharmacist for guidance, or follow local regulations for proper disposal.